The antineoplastic effect of low-molecular-weight heparins - a literature review

被引：14

作者：

Bochenek, Justyna ^{[1
]}

Pueskuellueoglu, Miroslawa ^{[1
]}

Krzemieniecki, Krzysztof ^{[1
]}

机构：

[1] Krakow Univ Hosp, Dept Clin Oncol, PL-31531 Krakow, Poland

来源：

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY | 2013年 / 17卷 / 01期

关键词：

heparins; cancer; tissue factor; chemokines; cellular interactions; venous thromboembolism; NON-ANTICOAGULANT HEPARINS; DEEP-VEIN THROMBOSIS; P-SELECTIN; VENOUS THROMBOEMBOLISM; ANTIMETASTATIC ACTIVITIES; TUMOR ANGIOGENESIS; CANCER METASTASIS; ELDERLY-PATIENTS; CLINICAL-TRIAL; RENAL-FUNCTION;

D O I：

10.5114/wo.2013.33766

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

There is some evidence for the antitumor effect of heparins, especially the low-molecular-weight ones. The authors discuss the potential mechanism of this antineoplastic effect and present results from several in vitro and in vivo experiments. The clinical trials concerning the impact of low-molecular-weight heparins on the tumor and on the patients' survival are described. The objective was to find out if heparins could be administered as an antitumor drug, independently of their anticoagulatory properties. The antitumor role of tissue factor, heparinase, chemokines, stromal proteins, cellular interactions as well as angiogenesis and immunology seems certain. The results of the available studies seem promising but large clinical trials are necessary in order to confirm the antineoplastic effect of the low-molecular-weight heparins and to approve them for standard anticancer treatment. It could be a breakthrough in modern oncology.

引用

页码：6 / 13

页数：8

共 68 条

[1] Can low-molecular-weight heparin improve the outcome of patients with operable non-small cell lung cancer? - An urgent call for research [J].

Alifano, M ;

Benedetti, G ;

Trisolini, R .

CHEST, 2004, 126 (02) :601-607

[2] A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer [J].

Altinbas, M ;

Coskun, HS ;

Er, O ;

Ozkan, M ;

Eser, B ;

Unal, A ;

Cetin, M ;

Soyuer, S .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (08) :1266-1271

[3] Antimetastatic effect of tinzaparin, a low-molecular-weight heparin [J].

Amirkhosravi, A ;

Mousa, SA ;

Amaya, M ;

Francis, JL .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2003, 1 (09) :1972-1976

[4] The role of tissue factor pathway inhibitor in tumor growth and metastasis [J].

Amirkhosravi, Ali ;

Meyer, Todd ;

Amaya, Mildred ;

Davila, Monica ;

Mousa, Shaker A. ;

Robson, Theresa ;

Francis, John L. .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (07) :643-652

[5] MOLECULAR-WEIGHT DEPENDENCY OF THE HEPARIN POTENTIATED INHIBITION OF THROMBIN AND ACTIVATED FACTOR-X - EFFECT OF HEPARIN NEUTRALIZATION IN PLASMA [J].

ANDERSSON, LO ;

BARROWCLIFFE, TW ;

HOLMER, E ;

JOHNSON, EA ;

SODERSTROM, G .

THROMBOSIS RESEARCH, 1979, 15 (3-4) :531-541

[6]

[Anonymous], 2019, NCCN CLIN PRACTICE G

[7]

BLAJCHMAN MA, 1989, ANN NY ACAD SCI, V556, P245

[8] Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis [J].

Borsig, L ;

Wong, R ;

Hynes, RO ;

Varki, NM ;

Varki, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (04) :2193-2198

[9] Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis [J].

Borsig, L ;

Wong, R ;

Feramisco, J ;

Nadeau, DR ;

Varki, NM ;

Varki, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (06) :3352-3357

[10] Antimetastatic activities of modified heparins: Selectin inhibition by heparin attenuates metastasis [J].

Borsig, Lubor .

SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (05) :540-546

← 1 2 3 4 5 6 7 →